ABSTRACT
Neutropenia caused by chemotherapy may delay treatment and reduce the therapeutic outcome. The objective of this study was to determine the difference in Absolute Neutrophil Count (ANC) recovery time between filgrastim brand name A and brand name B in patients with solid cancer at Dr. Sardjito Hospital, Yogyakarta, Indonesia. Data were obtained on the basis of the number of episodes of neutropenia. The result indicated an increased difference in ANC recovery time between filgrastim A administration at a dose of 6544.95 ± 6041.64/mm3 and filgrastim B administration at a dose of 7521.54 ± 7008.15/mm3. Through the survival analysis using the Kaplan—Meier curve, we revealed that there was no significant difference between the two types of filgrastim in achieving ANC recovery (p > 0.05). The results of the chi-square test indicated a significant difference between the grade of neutropenia and the time to achieve ANC recovery (p < 0.05). There was no statistically significant difference in the time required to achieve ANC recovery time between the brand names filgrastim A and filgrastim B.
